Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

A Faster Finish May Depend On A Better Start – EMA's PRIME Program

This article was originally published in The Pink Sheet Daily

Executive Summary

EMA officials spotlight need to improve clinical development plans in the early stages, with agency exec director Rasi saying many trials are "useless." They shy away from predicting timelines or goals for quicker reviews.

Advertisement

Related Content

European Notebook: All Change In The C-Suites; EMA PRIME Starts; French Experts Recommend Phase I Changes
PRIME Time: Smaller Companies In Focus As EMA Launches Priority Medicines Scheme
PRIME Time: Smaller Companies In Focus As EMA Launches Priority Medicines Scheme

Topics

Advertisement
UsernamePublicRestriction

Register

PS079280

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel